Original Article
Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes
N Engl J Med 2005; 353:1095-1104September 15, 2005
- Abstract
Background
Current guidelines recommend an early invasive strategy for patients who have acute coronary syndromes without ST-segment elevation and with an elevated cardiac troponin T level. However, randomized trials have not shown an overall reduction in mortality, and the reduction in the rate of myocardial infarction in previous trials has varied depending on the definition of myocardial infarction.
Methods
We randomly assigned 1200 patients with acute coronary syndrome without ST-segment elevation who had chest pain, an elevated cardiac troponin T level (≥0.03 μg per liter), and either electrocardiographic evidence of ischemia at admission or a documented history of coronary disease to an early invasive strategy or to a more conservative (selectively invasive) strategy. Patients received aspirin daily, enoxaparin for 48 hours, and abciximab at the time of percutaneous coronary intervention. The use of clopidogrel and intensive lipid-lowering therapy was recommended. The primary end point was a composite of death, nonfatal myocardial infarction, or rehospitalization for anginal symptoms within one year after randomization.
Results
The estimated cumulative rate of the primary end point was 22.7 percent in the group assigned to early invasive management and 21.2 percent in the group assigned to selectively invasive management (relative risk, 1.07; 95 percent confidence interval, 0.87 to 1.33; P=0.33). The mortality rate was the same in the two groups (2.5 percent). Myocardial infarction was significantly more frequent in the group assigned to early invasive management (15.0 percent vs. 10.0 percent, P=0.005), but rehospitalization was less frequent in that group (7.4 percent vs. 10.9 percent, P=0.04).
Conclusions
We could not demonstrate that, given optimized medical therapy, an early invasive strategy was superior to a selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation and with an elevated cardiac troponin T level.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Cumulative Rate of the Composite Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitalization for Anginal Symptoms within One Year.Figure 2
Estimated Rates and Relative Risks of the Composite Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitalization for Anginal Symptoms within One Year, According to Subgroup.Article Activity
- Article
Patients with acute coronary syndromes without ST-segment elevation are at risk for adverse cardiac events.1 Optimal treatment consists of intensive medical therapy followed by diagnostic coronary angiography and revascularization in some patients. In five large, randomized trials (Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital [VANQWISH], Fragmin and Fast Revascularization during Instability in Coronary Artery Disease [FRISC] II, Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18 [TACTICS–TIMI 18], TIMI IIIB, and the Third Randomized Intervention Treatment of Angina [RITA-3]), a routine, early invasive strategy (early angiography followed by revascularization, depending on angiographic findings) was compared with a “conservative” strategy (angiography and subsequent revascularization only if medical therapy failed or substantial residual ischemia was documented).2-6 An early invasive strategy was shown to be beneficial in the FRISC II, TACTICS–TIMI 18, and RITA-3 studies, especially in subgroups of patients at high risk, such as those presenting with an elevated cardiac troponin level. As a result, recent guidelines of the American College of Cardiology–American Heart Association and the European Society of Cardiology recommend an early invasive approach in high-risk patients with acute coronary syndromes without ST-segment elevation.7,8
Despite these recommendations, it is not clear that an early invasive strategy reduces mortality in this setting. A reduction in mortality was shown in the FRISC II study, but only among men. Such a reduction was not seen in any of the other studies. In addition, the reduction in the incidence of myocardial infarction associated with an early invasive strategy in these studies depended on the definition of myocardial infarction. Moreover, recent advances in medical therapy, such as the early use of clopidogrel and intensive lipid-lowering therapy, have been shown to improve the prognosis in patients with acute coronary syndromes.9,10 These therapies have not been tested in trials of early invasive strategies. Therefore, we conducted the present study to test the hypothesis that an early invasive strategy is superior to a selectively invasive strategy for patients who have acute coronary syndromes without ST-segment elevation and with an elevated cardiac troponin T level.
Methods
Study Population and Study Design
Between July 2001 and August 2003, 1200 patients were enrolled from 42 Dutch hospitals, 12 of which were high-volume centers with facilities for percutaneous coronary intervention and on-site cardiac surgery. The protocol was approved by all the local institutional review boards. All patients gave written informed consent. The trial was funded by a combination of sources. The sponsors had no involvement in the design of the study, data collection or analysis, or the writing of the manuscript.
Eligible patients had to have all three of the following: symptoms of ischemia that were increasing or occurred at rest, with the last episode occurring no more than 24 hours before randomization; an elevated cardiac troponin T level (≥0.03 μg per liter); and either ischemic changes as assessed by electrocardiography (defined as ST-segment depression or transient ST-segment elevation exceeding 0.05 mV, or T-wave inversion of ≥0.2 mV in two contiguous leads) or a documented history of coronary artery disease as evidenced by previous myocardial infarction, findings on previous coronary angiography, or a positive exercise test. Exclusion criteria were an age younger than 18 years or older than 80 years, myocardial infarction with ST-segment elevation in the past 48 hours, an indication for primary percutaneous coronary intervention or fibrinolytic therapy, hemodynamic instability or overt congestive heart failure, the use of oral anticoagulant drugs in the past 7 days, fibrinolytic treatment within the past 96 hours, percutaneous coronary intervention within the past 14 days, a contraindication to treatment with percutaneous coronary intervention or glycoprotein IIb/IIIa inhibitors, recent trauma or risk of bleeding, hypertension despite treatment (i.e., systolic pressure >180 mm Hg or diastolic pressure >100 mm Hg), weight greater than 120 kg, or inability to give informed consent.
Optimized Medical Therapy
The protocol specified that patients receive 300 mg of aspirin at the time of randomization, followed by at least 75 mg daily indefinitely, and enoxaparin (1 mg per kilogram of body weight, to a maximum of 80 mg) twice daily subcutaneously for at least 48 hours. Patients already started on unfractionated heparin were switched to enoxaparin immediately after randomization. The early use of clopidogrel (300 mg immediately, followed by 75 mg daily) in combination with aspirin was recommended to the investigators after the drug was approved in 2002 for the indication of acute coronary syndromes.9
All interventional procedures during the initial hospital phase were performed with the use of abciximab, given as a bolus dose of 0.25 mg per kilogram, followed by an infusion of 0.125 μg per kilogram per minute for 12 hours, and started 10 to 60 minutes before the first balloon inflation.11 Abciximab was also available for use in patients who subsequently underwent percutaneous revascularization. The protocol recommended intensive lipid-lowering therapy, preferably 80 mg of atorvastatin daily or the equivalent, started as soon as possible after randomization and continued indefinitely. The level of the MB isoform of creatine kinase (CK-MB) was measured at 6-hour intervals during the first period of 24 hours or more after admission, after each new clinical episode of ischemia, and after each percutaneous revascularization procedure.
Treatment Strategy
Patients were randomly assigned to an early invasive strategy or a selectively invasive strategy with the use of a central telephone system. Permuted-block randomization was performed, with stratification according to site, with block size randomly chosen to be four, six, or eight. Patients assigned to the early invasive strategy were scheduled to undergo angiography within 24 to 48 hours after randomization and percutaneous coronary intervention when appropriate on the basis of the coronary anatomy. Coronary-artery bypass grafting was recommended in patients with extensive three-vessel disease or severe left main-stem disease and was to be performed as soon as possible during the initial hospitalization period.
Patients assigned to the selectively invasive strategy were treated medically. These patients were scheduled to undergo angiography and subsequent revascularization only if they had refractory angina despite optimal medical treatment, hemodynamic or rhythmic instability, or clinically significant ischemia on the predischarge exercise test. Coronary angiography and revascularization after the initial hospital phase were performed if severe anginal symptoms (i.e., Canadian Cardiovascular Society [CCS] class III or IV) persisted despite optimal antianginal medication or if ischemia was documented on subsequent testing. Follow-up outpatient visits occurred at 1, 6, and 12 months after randomization.
End Points
The primary end point was a composite of death, recurrent myocardial infarction, or rehospitalization for angina within one year after randomization. Death was defined as death from any cause. Myocardial infarction was defined as documented myocardial necrosis, occurring either spontaneously or in the setting of percutaneous intervention, according to the recommendations of the Joint European Society of Cardiology–American College of Cardiology Committee for the Redefinition of Myocardial Infarction.12 Myocardial necrosis was defined by an elevation in the CK-MB level above the upper limit of normal. In the event of an elevated CK-MB level at randomization, recurrent myocardial infarction during the first 48 hours was diagnosed when there was a 50 percent decrease from a previous peak value, followed by a subsequent rise to a level exceeding the upper limit of normal. A myocardial infarction in the setting of coronary-artery bypass grafting required the occurrence of electrocardiographic evidence of new Q waves.
Major bleeding not related to coronary-artery bypass grafting during the index admission was defined by at least one of the following: fatal bleeding, intracranial bleeding, a need for blood transfusion, a decrease of 3 mmol per liter (4.8 g per deciliter) or more in hemoglobin levels, and bleeding resulting in hemodynamic compromise. All end points were adjudicated by members of an independent clinical end-points committee, who were unaware of the treatment assignments of the patients.
Statistical Analysis
We calculated that, given a 21 percent incidence of the primary end point in the group assigned to an early invasive strategy, 1200 patients would be needed to provide the study with 80 percent power to detect a relative risk reduction of 25 percent between the two groups, at an alpha level of 0.05. Continuous variables with normal distributions are expressed as means ±SD and were compared with the use of an unpaired Student's t-test. Categorical variables were compared with the use of Fisher's exact test or the chi-square test, where appropriate. All reported P values are two-sided and not adjusted for multiple testing.
Event rates at one year were estimated with the Kaplan–Meier method.13 Relative risks were calculated by dividing the Kaplan–Meier estimated rate of an event at one year in the early-invasive-strategy group by that in the group assigned to a selectively invasive strategy. The 95 percent confidence interval for the relative risk was calculated with the use of the standard errors from the Kaplan–Meier curve. The significance of differences in event rates between treatment groups was assessed with the use of the log-rank test. Data on patients who were lost to follow-up were censored at the time of the last contact.
Results
A total of 604 patients were randomly assigned to the early invasive strategy and 596 patients to the selectively invasive strategy. Baseline characteristics are shown in Table 1Table 1
Baseline Characteristics of the Patients.. The median age was 62 years, about three quarters of the patients were male, and 14 percent had diabetes. Cardiac catheterization was performed during the initial hospitalization in 98 percent of patients in the early-invasive-strategy group and 53 percent in the selectively-invasive-strategy group, and in 99 percent and 67 percent, respectively, within one year (Table 2Table 2
Cardiac Procedures within Two Days after Randomization, during Initial Hospitalization, and within One Year, According to Study Group.). Within one year, 79 percent of the patients in the early-invasive-strategy group had undergone revascularization, as compared with 54 percent in the selectively-invasive-strategy group. Eighty-eight percent of the percutaneous coronary intervention procedures in both treatment groups combined involved the placement of at least one stent. Medical therapy at discharge was similar between the group assigned to an early invasive strategy and the group assigned to a selectively invasive strategy, except for the use of clopidogrel (61 percent vs. 49 percent, respectively). The incidence of statin use at discharge was very high in both groups (90 percent and 94 percent, respectively).Primary End Point
Six patients were lost to follow-up before one year. A total of 263 patients (137 patients in the early-invasive-strategy group and 126 patients in the selectively-invasive-strategy group) reached the primary end point. Kaplan–Meier curves for the primary end point are shown in Figure 1Figure 1
Kaplan–Meier Estimates of the Cumulative Rate of the Composite Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitalization for Anginal Symptoms within One Year.. The estimated one-year cumulative event rate was 22.7 percent in the early-invasive-strategy group and 21.2 percent in the group assigned to a selectively invasive strategy (relative risk, 1.07; 95 percent confidence interval, 0.87 to 1.33; P=0.33) (Table 3Table 3
Cumulative Rate of the Composite Primary End Point and Its Components within One Year after Randomization.). One-year mortality was 2.5 percent in both groups (relative risk, 0.99; 95 percent confidence interval, 0.49 to 2.00; P=0.97). The cumulative risk of myocardial infarction within one year after randomization was significantly higher in the early-invasive-strategy group (15.0 percent vs. 10.0 percent; relative risk, 1.50; 95 percent confidence interval, 1.10 to 2.04; P=0.005). Rehospitalization was less frequent in the early-invasive-strategy group (7.4 percent vs. 10.9 percent; relative risk, 0.68; 95 percent confidence interval, 0.47 to 0.98; P=0.04).Several baseline clinical features were examined for potential effects in a subgroup analysis. The relative risks were not different among the major subgroups defined according to age, sex, the presence or absence of diabetes mellitus, the presence or absence of ST-segment deviation, or the level of cardiac troponin T (Figure 2Figure 2
Estimated Rates and Relative Risks of the Composite Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitalization for Anginal Symptoms within One Year, According to Subgroup.).Myocardial Infarction
Categories of infarct size according to peak CK-MB level are shown in Table 3. The rate of myocardial infarction among patients with a peak CK-MB level one to three times the upper limit of normal was significantly higher in the early-invasive-strategy group than in the group assigned to a selectively invasive strategy (7.2 percent vs. 4.6 percent, P=0.05). The incidence of myocardial infarction related to percutaneous coronary intervention or coronary-artery bypass grafting was also significantly higher in the early-invasive-strategy group (11.3 percent vs. 5.4 percent, P=0.001). To compare our results with those of previous trials, we applied the definitions of myocardial infarction from the FRISC II4 and the TACTICS–TIMI 185 studies to our data (Table 3). Applying these definitions lowered the rate of infarction. However, the relative risks remained essentially unaltered, and there were no significant differences in the rate of the composite primary end point between the groups, irrespective of the definition of infarction applied.
Other Secondary End Points
The percentage of patients free from anginal symptoms was similar in the early-invasive-strategy group and the group assigned to a selectively invasive strategy (86 percent and 87 percent, respectively). Moreover, the incidence of angina, defined as CCS class I to IV, was similar in the two groups (data not shown). Major bleeding not related to coronary-artery bypass grafting during the index admission occurred in 19 patients (3.1 percent) in the early-invasive-strategy group, as compared with 10 patients (1.7 percent) in the group assigned to a selectively invasive strategy.
Discussion
This study did not show that an early invasive strategy was superior to a selectively invasive strategy in patients who had an acute coronary syndrome without ST-segment elevation and who had an elevated cardiac troponin T level. Mortality within one year was low (2.5 percent in both groups), despite the fact that these patients were all considered at high risk. The incidence of myocardial infarction was significantly higher in the early-invasive-strategy group, particularly during hospitalization, confirming the finding of the FRISC II researchers4 that there is an early hazard associated with early revascularization. The incidence of the primary end point was 22.7 percent in the early-invasive-strategy group, but 21.2 percent in the group assigned to a selectively invasive strategy, which was lower than anticipated. There was no significant difference in the frequency of the primary end point among subgroups defined according to age, sex, the presence or absence of diabetes mellitus, the presence or absence of ST-segment deviation, or the level of cardiac troponin T.
Comparing the results of the present study with those of previous trials is not straightforward, owing to differences in study design, in the risk profile of patients included, in antithrombotic therapy, and in the definition of end points, in particular the definition of myocardial infarction; changes in the practice of invasive therapy (especially the use of stents and glycoprotein IIb/IIIa inhibitors); and the observed contrast between strategies in the rate and timing of revascularization. There are several possible explanations for the observed differences in outcome between the present study and previous trials.
First, revascularization rates were high in the two groups in our study (76 percent in the early-invasive-strategy group and 40 percent in the selectively-invasive-strategy group during the initial hospitalization, and 79 percent and 54 percent, respectively, within 1 year after randomization) as compared with those in TIMI-IIIb (64 percent vs. 58 percent at 1 year), VANQWISH (44 percent vs. 33 percent at 23 months), FRISC II (71 percent vs. 9 percent at 10 days, and 77 percent vs. 37 percent at 6 months), TACTICS–TIMI 18 (61 percent vs. 44 percent at 6 months), and RITA-3 (44 percent vs. 10 percent during the index admission, and 57 percent vs. 28 percent within 1 year).14 As in the VANQWISH trial, all patients in our study had evidence of myocardial necrosis, as compared with 58 percent with an elevated troponin level in FRISC II, 54 percent in TACTICS–TIMI 18, and 75 percent in RITA-3. The fact that all patients in the present study were at high risk (as evidenced by an elevated troponin level) may explain the earlier and more frequent revascularization in the group assigned to a selectively invasive strategy in our study. The 40 percent rate of revascularization during the initial hospitalization in the group assigned to a selectively invasive strategy in our study compares well with the 48 percent rate of revascularization in patients with acute coronary syndromes who were admitted to centers with catheterization facilities in the global registry of acute coronary events (the GRACE registry), which reflects real-world clinical practice.15
Second, as in FRISC II, most myocardial infarctions in the early-invasive-strategy group in our study were procedure-related.16 The higher incidence of myocardial infarction in this group is driven in large part by relatively small infarctions related to percutaneous coronary intervention that were detected with carefully timed and frequent measurements of CK-MB levels. Moreover, we applied the Joint European Society of Cardiology – American College of Cardiology definitions of spontaneous and percutaneous coronary intervention–related myocardial infarction (peak CK-MB level, greater than the upper limit of normal).12 Different cutoff levels for infarctions related to percutaneous coronary intervention were used in FRISC II (CK-MB level, >1.5 times the upper limit of normal), TACTICS–TIMI 18 (CK-MB level, ≥3 times the upper limit of normal), and RITA-3 and Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) (CK-MB level, 2 times the upper limit of normal). The incidence of myocardial infarction in the early-invasive-strategy group in our study (15.0 percent at 1 year; median time to percutaneous coronary intervention, 23 hours) was similar to that in the recent SYNERGY trial (11.7 percent at 30 days; median time to percutaneous coronary intervention, 23 hours), in which an early-intervention strategy was used.17
The prognostic implications of periprocedural myocardial damage are controversial, but some reports suggest that the prognosis of patients with such injury should be regarded as similar to that of patients with spontaneous necrosis.16,18,19 To determine whether the increased incidence of procedure-related myocardial infarction in the early-invasive-strategy group in our study eventually results in a worse prognosis will require long-term follow-up. Regardless of the definition of myocardial infarction in our study, we could not demonstrate a significant difference in the incidence of the composite primary end point between the two treatment strategies.
Third, the incidence of myocardial infarction in the group assigned to a selectively invasive strategy was lower than expected. We incorporated recent advances in background medical therapy, such as the use of abciximab at the time of percutaneous coronary intervention procedures, the early use of clopidogrel, and intensive lipid-lowering therapy, which have been shown to improve outcomes in patients who have acute coronary syndromes without ST-segment elevation.10,20 This may partially explain the lower-than-expected event rate in the group assigned to a selectively invasive strategy.
Finally, all procedures were performed in high-volume centers with facilities for cardiac surgery on site, resulting in a low overall mortality, including a low mortality related to coronary-artery bypass grafting. In our view, advances in background medical therapy in combination with better detection of myocardial infarctions with frequent, carefully timed measurements of CK-MB levels best explain the differences between our results and those of previous trials.
The 2003 European Society of Cardiology guidelines were published during the study enrollment period. Physicians familiar with the guidelines would probably be inclined to favor performing angiography in most patients with an elevated cardiac troponin T level. As a result, physicians participating in our study might have enrolled lower-risk patients than would otherwise have been included. However, baseline characteristics suggest that we studied a high-risk population, with more than one third of the patients already taking aspirin, more than half having ischemic changes as assessed by electrocardiography, and all having an elevated cardiac troponin T level as confirmed with core laboratory analysis.
We did not find the expected 25 percent reduction in the cumulative rate of the primary end point with an early invasive strategy as compared with a selectively invasive strategy. As a result, the confidence interval around the relative risk of the composite end point of death, myocardial infarction, or rehospitalization for angina was 0.87 to 1.33, corresponding to a possible reduction in risk of 13 percent (or an increase in risk of 33 percent) with an early invasive strategy. However, the point estimate for the relative risk (1.07) actually favors the selectively invasive approach, and even the most substantial advantage of early invasive management consistent with our data is much less than that estimated in previous large trials.
Among patients with acute coronary syndromes without ST-segment elevation who have an elevated cardiac troponin T level, we could not demonstrate that an early invasive strategy was superior to a selectively invasive strategy. These results were obtained with the use of contemporary medical therapy that included low-molecular-weight heparin, glycoprotein IIb/IIIa inhibition at the time of percutaneous procedures, clopidogrel, and intensive lipid-lowering therapy.
Supported by the Interuniversity Cardiology Institute of the Netherlands, the Working Group on Cardiovascular Research in the Netherlands, and educational grants from Eli Lilly, Sanofi-Synthelabo, Aventis, Pfizer, and Medtronic.
Dr. Michels reports having received grant support from Eli Lilly NL, and Dr. Verheugt consulting fees and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, Merck, and Bayer AG.
We are indebted to Roche Diagnostics in the Netherlands for providing the device for the bedside cardiac troponin T measurements (Cardiac Reader) and the reagents for core laboratory troponin T measurements; to all the investigators and coordinators of the ICTUS trial; to all the medical and nursing staff in the recruitment and intervention centers who made the trial possible; to Karla Mulder for database management; to Alexander Hirsch, Marc van der Zee, Margriet Klees, and Wilma van der Wateren for data collection and analysis; to Jan van Straalen and Johan Fischer for invaluable assistance with laboratory measurements; and to all the patients who participated in the trial.
Source Information
From the Academisch Medisch Centrum, Amsterdam (R.J.W., F.W., G.T.S., J.G.P.T.); Medisch Centrum Alkmaar, Alkmaar (J.H.C.); Amphia Ziekenhuizen, Breda (P.H.J.M.D.); WestFriesGasthuis, Hoorn (C.L.J.); Elkerliek Ziekenhuis, Helmond (P.E.F.B.); Catharina Ziekenhuis, Eindhoven (H.R.M.); and Universitair Medisch Centrum St. Radboud, Nijmegen (F.W.A.V.) — all in the Netherlands.
Address reprint requests to Dr. de Winter at the Department of Cardiology, B2-137, Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, the Netherlands, or at r.j.dewinter@amc.uva.nl.
The ICTUS trial investigators are listed in the Appendix.
Appendix
The following investigators and research coordinators, all in the Netherlands, participated in the ICTUS trial (total number of patients recruited are indicated in parentheses): Academisch Medisch Centrum, Amsterdam (105) — R.J.G. Peters; Amphia Ziekenhuis, Breda (101) — P.H.J.M. Dunselman; Universitair Medisch Centrum St. Radboud, Nijmegen (78) — F.W.A. Verheugt; Westfries Gasthuis, Hoorn (74) — C.L. Janus; Medisch Centrum Alkmaar, Alkmaar (72) — V. Umans; Elkerliek Ziekenhuis, Helmond (65) — P.E.F. Bendermacher; Catharina Ziekenhuis, Eindhoven (59) — H.R. Michels; Flevoziekenhuis, Almere (48) — A. Sadée; Canisius-Wilhelmina, Nijmegen (46) — D. Hertzberger; Maasziekenhuis, Boxmeer (40) — J. Peters; Ziekenhuis Hilversum, Hilversum (40) — P.A.R.M. de Miliano; Oosterschelde Ziekenhuis, Goes (38) — A.H. Liem; Rijnstate Ziekenhuis, Arnhem (38) — R. Tjon Joe Gin; Christelijk Ziekenhuis Nij Smellinghe, Drachten (36) — M. van der Linde; Deventer Ziekenhuis, Deventer (36) — D. Lok; Ziekenhuis Gooi-Noord, Blaricum (35) — G. Hoedemaker; Boven IJ Ziekenhuis, Amsterdam (28) — M. Pieterse; Scheperziekenhuis, Emmen (27) — L. van den Merkhof; Jeroen Bosch Ziekenhuis, Den Bosch (25) — M. Daniëls; Groene Hart Ziekenhuis, Gouda (20) — M. van Hessen; St. Elisabeth Ziekenhuis, Tilburg (19) — W. Hermans; Slotervaart Ziekenhuis, Amsterdam (18) — C.E. Schotborgh; AZM, Maastricht (18) — C. de Zwaan; Diakonessenhuis, Utrecht (17) — A. Bredero; Universitair Medisch Centrum, Utrecht (17) — P. de Jaegere; Kennemer Gasthuis, Haarlem (14) — M. Janssen; Medisch Spectrum Twente, Enschede (11) — J. Louwerenburg; St. Franciscus, Rotterdam (11) — M. Veerhoek; LUMC, Leiden (11) — M. Schalij; Gemini Ziekenhuis, Den Helder (10) — A. de Porto; UMCG, Groningen (10) — F. Zijlstra; Tweesteden Ziekenhuis, Tilburg (10) — J. Winter; Erasmus MC, Rotterdam (8) — P. de Feyter; Ziekenhuis Leyenburg Den Haag (7) — R. Robles de Medina; Reinier de Graaf Gasthuis, Delft (6) — P. Withagen; Bronovo Ziekenhuis, Den Haag (5) — M. Sedney; Maxima Medisch Centrum, Veldhoven (4) — H. Thijssen; Rijnland Ziekenhuis, Leiderdorp (3) — C. van Rees; Streekziekenhuis Zevenaar, Zevenaar (2) — P. van den Bergh; VUMC, Amsterdam (1) — C. de Cock; Isala klinieken, Zwolle — A. van 't Hof; St. Antonius Ziekenhuis, Nieuwegein — M.J. Suttorp; Trial Steering Committee — R.J. de Winter (chair), F. Windhausen, J.H. Cornel, J.G.P. Tijssen, F.W.A. Verheugt, P.H.J.M. Dunselman, P.J. de Feyter, H.R. Michels; Executive Committee — R.J. de Winter, F. Windhausen, J.G.P. Tijssen; End Point Adjudication Committee — D. Düren, K. Liem; Data Center and Monitoring — Academisch Medisch Centrum, Amsterdam; Clinical Chemistry Core Laboratory — Academisch Medisch Centrum, Amsterdam, Laboratory of Clinical Chemistry, G.T.B. Sanders, J. Fischer, J. van Straalen.
- References
References
1
Hamm CW ,Braunwald E . A classification of unstable angina revisited. Circulation 2000;102:118-122
Web of Science | Medline2
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994;89:1545-1556
Web of Science | Medline3
Boden WE ,O'Rourke RA ,Crawford MH , et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-1792[Erratum, N Engl J Med 1998;339:1091.]
Full Text | Web of Science | Medline4
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-715
CrossRef | Web of Science | Medline5
Cannon CP ,Weintraub WS ,Demopoulos LA , et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887
Full Text | Web of Science | Medline6
Fox KA ,Poole-Wilson PA ,Henderson RA , et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-751
CrossRef | Web of Science | Medline7
Bertrand ME ,Simoons ML ,Fox KA , et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840[Erratum, Eur Heart J 2003;24:485, 1174-5.]
CrossRef | Web of Science | Medline8
Braunwald E ,Antman EM ,Beasley JW , et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction -- summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374
CrossRef | Web of Science | Medline9
Yusuf S ,Zhao F ,Mehta SR , et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502[Erratum, N Engl J Med 2001;345:1506, 1716.]
Full Text | Web of Science | Medline10
Cannon CP ,Braunwald E ,McCabe CH , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
Full Text | Web of Science | Medline11
Topol EJ ,Moliterno DJ ,Herrmann HC , et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894
Full Text | Web of Science | Medline12
Alpert JS ,Thygesen K ,Antman E ,Bassand JP . Myocardial infarction redefined -- a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-969[Erratum, J Am Coll Cardiol 2001;37:973.]
CrossRef | Web of Science | Medline13
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science14
Boden WE . “Routine invasive“ versus “selective invasive“ approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. J Am Coll Cardiol 2003;41:Suppl:113S-122S
CrossRef | Web of Science | Medline15
Van de Werf F ,Gore JM ,Avezum A , et al. Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. BMJ 2005;330:441-447
CrossRef | Web of Science | Medline16
Lagerqvist B ,Husted S ,Kontny F , et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002;40:1902-1914
CrossRef | Web of Science | Medline17
Ferguson JJ ,Califf RM ,Antman EM , et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54
CrossRef | Web of Science | Medline18
Akkerhuis KM ,Alexander JH ,Tardiff BE , et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-556
CrossRef | Web of Science | Medline19
Roe MT ,Mahaffey KW ,Kilaru R , et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004;25:313-321
CrossRef | Web of Science | Medline20
Ferguson JJ ,Antman EM ,Bates ER , et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-634
CrossRef | Web of Science | Medline
- Citing Articles (160)
Citing Articles
1
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
CrossRef2
Kaspar Broch, Christian Eek, Ragnhild Wergeland, Thor Ueland, Rita Skårdal, Pål Aukrust, Helge Skulstad, Lars Gullestad. (2011) NT-proBNP predicts myocardial recovery after non-ST-elevation acute coronary syndrome. Scandinavian Cardiovascular Journal1-19
CrossRef3
Pravin Pratap, Sameer Gupta, Michael Berlowtiz. (2011) Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach. Journal of Cardiovascular Translational Research
CrossRef4
H. Thiele, J. Rach, N. Klein, D. Pfeiffer, A. Hartmann, R. Hambrecht, P. Sick, I. Eitel, S. Desch, G. Schuler, . (2011) Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). European Heart Journal
CrossRef5
Mohammed Reza Movahed, Jooby John, Mehrnoosh Hashemzadeh, Mehrtash Hashemzadeh. (2011) Mortality Trends for Non-ST-segment Elevation Myocardial Infarction (NSTEMI) in the United States from 1988 to 2004. Clinical Cardiology 34:11, 689-692
CrossRef6
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef7
Peter R. Sinnaeve. (2011) Routine Invasive Versus Conservative Management in Non-ST-elevation Acute Coronary Syndromes. Journal of Cardiovascular Translational Research
CrossRef8
Inder M. Singh, David R. Holmes. (2011) Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. Current Problems in Cardiology 36:10, 375-401
CrossRef9
MENG JIANG, BEN HE, QI ZHANG. (2011) Timing of Early Invasive Intervention in Patients with Moderate to High Risk Acute Coronary Syndromes. Journal of Interventional Cardiologyno-no
CrossRef10
Michael Christ, Thomas Bertsch, Steffen Popp, Philipp Bahrmann, Hans-Jürgen Heppner, Christian Müller. (2011) High-sensitivity troponin assays in the evaluation of patients with acute chest pain in the emergency department. Clinical Chemistry and Laboratory Medicine---
CrossRef11
Peter Damman, Lene Holmvang, Jan G.P. Tijssen, Bo Lagerqvist, Tim C. Clayton, Stuart J. Pocock, Fons Windhausen, Alexander Hirsch, Keith A.A. Fox, Lars Wallentin, Robbert J. de Winter. (2011) Usefulness of the Admission Electrocardiogram to Predict Long-Term Outcomes After Non-ST-Elevation Acute Coronary Syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). The American Journal of Cardiology
CrossRef12
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal
CrossRef13
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef14
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef15
Daisuke Hachinohe, Myung Ho Jeong, Shigeru Saito, Khurshid Ahmed, Seung Hwan Hwang, Min Goo Lee, Doo Sun Sim, Keun-Ho Park, Ju Han Kim, Young Joon Hong, Youngkeun Ahn, Jung Chaee Kang, Jong Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung Ho Hur, In Whan Seong, Taek Jong Hong, Donghoon Choi, Myeong Chan Cho, Chong Jin Kim, Ki Bae Seung, Wook Sung Chung, Yang Soo Jang, Seung Woon Rha, Jang Ho Bae, Seung Jung Park. (2011) Management of Non–ST-Segment Elevation Acute Myocardial Infarction in Patients With Chronic Kidney Disease (from the Korea Acute Myocardial Infarction Registry). The American Journal of Cardiology 108:2, 206-213
CrossRef16
Noah Vale, Alain J Nordmann, Gregory G Schwartz, James de Lemos, Furio Colivicchi, Frank den Hartog, Petr Ostadal, Stella M Macin, Anho H Liem, Edward Mills, Neera Bhatnagar, Heiner C Bucher, Matthias Briel, Matthias Briel. 2011. Statins for acute coronary syndrome. .
CrossRef17
Joshua Lehrer, David P. Lee. 2011. Unstable Angina and Non-ST Elevation Myocardial Infarction. , 43-52.
CrossRef18
J. Douglas Kirk, Michael Kontos, Deborah B. Diercks. (2011) Upstream treatment of acute coronary syndrome in the ED. The American Journal of Emergency Medicine 29:4, 446-456
CrossRef19
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef20
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef21
Christian W. Hamm, Albrecht Elsaesser. 2011. Indications in Acute Coronary Syndromes without ST Elevation (NSTE-ACS). , 232-241.
CrossRef22
Clara Carpeggiani, Patrizia Landi, Claudio Michelassi, Elena Barberini, Antonio L'Abbate. (2011) Long-term prognosis in stable angina; medical treatment or coronary revascularization in patients younger than 70years?. International Journal of Cardiology 148:1, 43-47
CrossRef23
Patricia Palau, Julio Núñez, Juan Sanchis, Oliver Husser, Vicente Bodí, Eduardo Núñez, Gema Miñana, Line Boesen, Silvia Ventura, Angel Llàcer. (2011) Differential Prognostic Effect of Revascularization According to a Simple Comorbidity Index in High-Risk Non-ST-Segment Elevation Acute Coronary Syndrome. Clinical Cardiologyn/a-n/a
CrossRef24
Manuel Piqué, Isabel Hernández, Antonio Miñano, Fernando Worner Diz. (2011) Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS. Revista Española de Cardiología Suplementos 11, 27-32
CrossRef25
G. Ganesha Babu, J. Malcolm Walker, D. M. Yellon, D. J. Hausenloy. (2011) Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. European Heart Journal 32:1, 23-31
CrossRef26
D. G. Katritsis, G. C. M. Siontis, A. Kastrati, A. W. J. van't Hof, F.-J. Neumann, K. C. M. Siontis, J. P. A. Ioannidis. (2011) Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. European Heart Journal 32:1, 32-40
CrossRef27
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef28
Michael C. Kontos, James A. de Lemos, Fang-Shu Ou, Stephan D. Wiviott, Joanne M. Foody, L. Kristin Newby, Anita Chen, Matthew T. Roe. (2010) Troponin-positive, MB-negative patients with non–ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network–Get With The Guidelines (NCDR ACTION-GWTG) Registry. American Heart Journal 160:5, 819-825
CrossRef29
Alexandre Cochet, Alain Lalande, Luc Lorgis, Marianne Zeller, Jean-Claude Beer, Paul M. Walker, Claude Touzery, Jean-Eric Wolf, Yves Cottin, François Brunotte. (2010) Prognostic Value of Microvascular Damage Determined by Cardiac Magnetic Resonance in Non ST-Segment Elevation Myocardial Infarction. Investigative Radiology 45:11, 725-732
CrossRef30
Juan Sanchis, Vicent Bodí, Julio Núñez, Eduardo Núñez. (2010) Conservative, True Selective Invasive, and Routine Invasive Strategies in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 56:19, 1609
CrossRef31
Charles V. Pollack, George W. Christy. (2010) Acute coronary syndromes: Long-term impact of routine versus invasive ACS management. Nature Reviews Cardiology 7:10, 544-546
CrossRef32
Kouraki Kleopatra, Kerstin Muth, Ralf Zahn, Timm Bauer, Oliver Koeth, Claus Jünger, Anselm Gitt, Jochen Senges, Uwe Zeymer. (2010) Effect of an invasive strategy on in-hospital outcome and one-year mortality in women with non-ST-elevation myocardial infarction. International Journal of Cardiology
CrossRef33
Rajendra H. Mehta, Anita Y. Chen, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Matthew T. Roe. (2010) Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non–ST-segment elevation myocardial infarction. American Heart Journal 160:3, 405-411
CrossRef34
Volker Schächinger, Christian Herdeg, Bruno Scheller. (2010) Best way to revascularize patients with main stem and three vessel lesions: patients should undergo PCI!. Clinical Research in Cardiology 99:9, 531-539
CrossRef35
F. Felices-Abad, J. Latour-Pérez, M.P. Fuset-Cabanes, M. Ruano-Marco, J. Cuñat-de la Hoz, F. del Nogal-Sáez. (2010) Indicadores de calidad en el síndrome coronario agudo para el análisis del proceso asistencial pre e intrahospitalario. Medicina Intensiva 34:6, 397-417
CrossRef36
Patricia Palau, Julio Núñez, Juan Sanchis, Vicent Bodí, Eva Rumiz, Eduardo Núñez, Gema Miñana, Pilar Merlos, Cristina Gómez, Lorenzo Fácila, Francisco J. Chorro, Àngel Fácila. (2010) Impacto pronóstico de una estrategia invasiva en el síndrome coronario agudo sin elevación del segmento ST según la presencia o no de disfunción sistólica. Revista Española de Cardiología 63:8, 915-924
CrossRef37
Benjamin J.W. Chow, Phil Joseph, Yeung Yam, Malek Kass, Li Chen, Rob S. Beanlands, Terrence D. Ruddy. (2010) Usefulness of Computed Tomographic Coronary Angiography in Patients With Acute Chest Pain With and Without High-Risk Features. The American Journal of Cardiology 106:4, 463-469
CrossRef38
Keith A.A. Fox, Tim C. Clayton, Peter Damman, Stuart J. Pocock, Robbert J. de Winter, Jan G.P. Tijssen, Bo Lagerqvist, Lars Wallentin. (2010) Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 55:22, 2435-2445
CrossRef39
Enrico Orsini, Giovanni Battista Zito. (2010) Matching pathophysiology and evidence-based medicine for optimal management of ischemic heart disease. Journal of Cardiovascular Medicine 11:6, 469-476
CrossRef40
Jon C. George, David J. Moliterno, George D. Dangas. (2010) American College of Cardiology Annual Scientific Session 2010. JACC: Cardiovascular Interventions 3:5, 562-564
CrossRef41
José G. Díez, James M. Wilson. (2010) Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory. Cardiovascular Drugs and Therapy 24:2, 161-174
CrossRef42
Benjamin M. Scirica. (2010) Acute Coronary Syndrome. Journal of the American College of Cardiology 55:14, 1403-1415
CrossRef43
Michel R Hoenig, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2010. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. .
CrossRef44
Patrick T. O'Gara. (2010) The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. Journal of the American College of Cardiology 55:13, 1359-1361
CrossRef45
John A. Bittl, David J. Maron. (2010) Having It Both Ways. Journal of the American College of Cardiology 55:9, 865-866
CrossRef46
Marc W. Deyell, William A. Ghali, David B. Ross, Jianguo Zhang, Brenda R. Hemmelgarn. (2010) Timing of nonemergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome. American Heart Journal 159:3, 490-496
CrossRef47
Peter Damman, Alexander Hirsch, Fons Windhausen, Jan G.P. Tijssen, Robbert J. de Winter. (2010) 5-Year Clinical Outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) Trial. Journal of the American College of Cardiology 55:9, 858-864
CrossRef48
Sanjay Kaul, George A. Diamond. (2010) Trial and Error. Journal of the American College of Cardiology 55:5, 415-427
CrossRef49
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef50
Esam Elbarasi, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Jan Kornder, Graham C. Wong, Jean-Pierre Déry, Fred Anderson, Joel M. Gore, Keith A.A. Fox, Andrew T. Yan. (2010) Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal 159:1, 40-46
CrossRef51
Hae Chang Jeong, Youngkeun Ahn, Myung Ho Jeong, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park, . (2010) Long-Term Clinical Outcomes according to Initial Management and Thrombolysis In Myocardial Infarction Risk Score in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction. Yonsei Medical Journal 51:1, 58
CrossRef52
Erlend Aune, Knut Endresen, Keith A.A. Fox, Jon Erik Steen-Hansen, Jo Roislien, Joran Hjelmesaeth, Jan Erik Otterstad. (2010) Effect of Implementing Routine Early Invasive Strategy on One-Year Mortality in Patients With Acute Myocardial Infarction. The American Journal of Cardiology 105:1, 36-42
CrossRef53
Sean Jedrzkiewicz, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Jan Kornder, J. Paul DeYoung, Graham C. Wong, Barry Rose, François R. Grondin, Richard Gallo, Wei Huang, Joel M. Gore, Andrew T. Yan. (2009) Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. Canadian Journal of Cardiology 25:11, e370-e376
CrossRef54
Jaume Figueras, Magda Heras, Francisco Baigorri, Roberto Elosua, Ignacio Ferreira, Miquel Santaló. (2009) Resultados del III registro IAM CAT de pacientes con infarto de miocardio con elevación del segmento ST en Cataluña. Comparación con los registros IAM CAT I y II. Medicina Clínica 133:18, 694-701
CrossRef55
Julio Núñez, Juan Sanchis, Vicent Bodí. (2009) Estrategia de revascularización invasiva en el síndrome coronario sin elevación del segmento ST. El debate continúa. Medicina Clínica 133:18, 717-723
CrossRef56
William E. Boden, Vipul Gupta. (2009) Acute Coronary Syndromes: Selective vs Early Invasive Strategies. Clinical Cardiology 32:11, 621-626
CrossRef57
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef58
Brian J. Potter, Marc Dorais, Samer Mansour, Katarzyna Orlicka, François Gobeil, Stéphane Rinfret. (2009) Effectiveness of Myocardial Perfusion Scintigraphy to Predict Coronary Anatomy in Patients with Non-ST Elevation Acute Coronary Syndrome. The American Journal of Cardiology 104:5, 644-647
CrossRef59
S. Michael Gharacholou, Karen P. Alexander. (2009) Evolving role of revascularization in older adults with acute coronary syndrome. Current Cardiovascular Risk Reports 3:5, 355-365
CrossRef60
Abhiram Prasad, Bernard J. Gersh, Michel E. Bertrand, A. Michael Lincoff, Jeffrey W. Moses, E. Magnus Ohman, Harvey D. White, Stuart J. Pocock, Brent T. McLaurin, David A. Cox, Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone. (2009) Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 54:5, 477-486
CrossRef61
Johan Herlitz, Mikael Dellborg, Thomas Karlsson, Maria Haglid Evander, Marianne Hartford, Elisabeth Perers, Kenneth Caidahl. (2009) Treatment and outcome in acute myocardial infarction in a community in relation to gender. International Journal of Cardiology 135:3, 315-322
CrossRef62
C. Berry, K. S. Pieper, H. D. White, S. D. Solomon, F. Van de Werf, E. J. Velazquez, A. P. Maggioni, R. M. Califf, M. A. Pfeffer, J. J.V. McMurray. (2009) Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 30:12, 1450-1456
CrossRef63
Mehta, Shamir R., Granger, Christopher B., Boden, William E., Steg, Philippe Gabriel, Bassand, Jean-Pierre, Faxon, David P., Afzal, Rizwan, Chrolavicius, Susan, Jolly, Sanjit S., Widimsky, Petr, Avezum, Alvaro, Rupprecht, Hans-Jurgen, Zhu, Jun, Col, Jacques, Natarajan, Madhu K., Horsman, Craig, Fox, Keith A.A., Yusuf, Salim, . (2009) Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine 360:21, 2165-2175
Full Text64
J. Hoekstra, M. Cohen. (2009) Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines. International Journal of Clinical Practice 63:4, 642-655
CrossRef65
Charles V. Pollack, Judd E. Hollander, Anita Y. Chen, Eric D. Peterson, Sripal Bangalore, Frank W. Peacock, Christopher P. Cannon, John G. Canto, Brian W. Gibler, Magnus E. Ohman, Matthew T. Roe. (2009) Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:1, 29-33
CrossRef66
E. Swahn, J. Alfredsson, R. Afzal, A. Budaj, S. Chrolavicius, K. Fox, S. Jolly, S. R. Mehta, R. de Winter, S. Yusuf. (2009) Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. European Heart Journal
CrossRef67
Stefano Savonitto, Nuccia Morici, Alice Sacco, Silvio Klugmann. (2009) Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients. Future Cardiology 5:1, 27-41
CrossRef68
L.M. Dijksman, A. Hirsch, F. Windhausen, F.F. Asselman, J.G.P. Tijssen, M.G.W. Dijkgraaf, R.J. de Winter. (2009) Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. International Journal of Cardiology 131:2, 204-211
CrossRef69
William S Weintraub. (2008) Is an invasive interventional strategy of value in non-ST-elevation acute coronary syndromes?. Nature Clinical Practice Cardiovascular Medicine 5:12, 754-755
CrossRef70
Pieter J. Vlaar, Gilles F. Diercks, Tone Svilaas, Mathijs Vogelzang, Bart J. de Smet, Ad F. van den Heuvel, Rutger L. Anthonio, Gillian A. Jessurun, Eng-Shiong Tan, Albert J. Suurmeijer, Felix Zijlstra. (2008) The feasibility and safety of routine thrombus aspiration in patients with non-ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions 72:7, 937-942
CrossRef71
Pierluigi Tricoci. (2008) Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?. Current Opinion in Cardiology 23:6, 585-590
CrossRef72
Marc Cohen, James Hoekstra. (2008) The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. The American Journal of Emergency Medicine 26:8, 932-941
CrossRef73
Marc Cohen. (2008) High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment. Cardiovascular Drugs and Therapy 22:5, 407-418
CrossRef74
R. Zahn, U. Zeymer. (2008) Interventionelle Therapie des akuten Herzinfarkts. Der Internist 49:9, 1038-1046
CrossRef75
A. Hirsch, F. Windhausen, J. G.P. Tijssen, A. J.M. Oude Ophuis, W. J. van der Giessen, P. M. van der Zee, J. H. Cornel, F. W.A. Verheugt, R. J. de Winter, . (2008) Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. European Heart Journal 30:6, 645-654
CrossRef76
J. Matthew Brennan, John L. Petersen. (2008) Early intervention: Which patients and how early?. Current Cardiology Reports 10:4, 303-311
CrossRef77
Rahul K. Khare, D. Mark Courtney, Emilie S. Powell, Arjun K. Venkatesh, Todd A. Lee. (2008) Sixty-four-slice Computed Tomography of the Coronary Arteries: Cost-Effectiveness Analysis of Patients Presenting to the Emergency Department with Low-risk Chest Pain. Academic Emergency Medicine 15:7, 623-632
CrossRef78
Victor Novack, Donald E. Cutlip, Alan Jotkowitz, Nicky Lieberman, Avi Porath. (2008) Reduction in Sex-Based Mortality Difference with Implementation of New Cardiology Guidelines. The American Journal of Medicine 121:7, 597.e1-597.e8
CrossRef79
Matthew T. Roe, Anita Y. Chen, Elizabeth R. Delong, William E. Boden, James E. Calvin, Charles B. Cairns, Sidney C. Smith, Charles V. Pollack, Ralph G. Brindis, Robert M. Califf, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson. (2008) Patterns of transfer for patients with non–ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. American Heart Journal 156:1, 185-192
CrossRef80
Finlay A. McAlister, Hude Quan, Andrew Fong, Yan Jin, Bibiana Cujec, David Johnson. (2008) Effect of Invasive Coronary Revascularization in Acute Myocardial Infarction on Subsequent Death Rate and Frequency of Chronic Heart Failure. The American Journal of Cardiology 102:1, 1-5
CrossRef81
Javier Jiménez-Candil, Maximiliano Diego, Ignacio Cruz González, José M. González Matas, Francisco Martín, Pedro Pabón, Víctor Ramírez, Víctor León, Cándido Martín-Luengo. (2008) Relationship between the QTc interval at hospital admission and the severity of the underlying ischaemia in low and intermediate risk people studied for acute chest pain. International Journal of Cardiology 126:1, 84-91
CrossRef82
Charles V. Pollack, Eugene Braunwald. (2008) 2007 Update to the ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine 51:5, 591-606
CrossRef83
Bertrand Renaud, Patrick Maison, Alfred Ngako, Patrick Cunin, Aline Santin, Jérôme Hervé, Mirna Salloum, Marie-Jeanne Calmettes, Cyril Boraud, Virginie Lemiale, Jean Claude Grégo, Marie Debacker, François Hémery, Eric Roupie. (2008) Impact of Point-of-care Testing in the Emergency Department Evaluation and Treatment of Patients with Suspected Acute Coronary Syndromes. Academic Emergency Medicine 15:3, 216-224
CrossRef84
Stefano Savonitto, Stefano De Servi, Anna Sonia Petronio, Leonardo Bolognese, Claudio Cavallini, Cesare Greco, Ciro Indolfi, Luigi Oltrona Visconti, Federico Piscione, Giuseppe Ambrosio, Marcello Galvani, Antonio Marzocchi, Ignazio Santilli, Giuseppe Steffenino, Attilio Maseri. (2008) Early aggressive vs. initially conservative treatment in elderly patients with non-ST-elevation acute coronary syndrome: The Italian Elderly ACS study. Journal of Cardiovascular Medicine 9:3, 217-226
CrossRef85
William E. Boden, Prediman K. Shah, Vipul Gupta, E. Magnus Ohman. (2008) Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases 50:5, 311-351
CrossRef86
Michael W. Rich. 2008. Therapy of Acute Myocardial Infarction. , 293-326.
CrossRef87
Gregory G Schwartz. (2008) Lipid management after acute coronary syndrome. Current Opinion in Internal Medicine 7:1, 75-81
CrossRef88
William Cahoon, Maureen P. Flattery. (2008) ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. Progress in Cardiovascular Nursing 23:1, 53-56
CrossRef89
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef90
José A. Alvarez Tamargo, Eugenio Simarro Martín-Ambrosio, Enrique Romero Tarín, María Martín Fernández, Sergio Hevia Nava, Vicente Barriales Alvarez, Cesar Morís de la Tassa. (2008) Angiographic Correlates of the Treadmill Scores in Non-High-Risk Patients with Unstable Angina. Cardiology 109:1, 1-9
CrossRef91
Michael G. Millin, Steven C. Brooks, Andrew Travers, Ross E. Megargel, M. Riccardo Colella, Robert A. Rosenbaum, Tom P. Aufderheide. (2008) Emergency Medical Services Management of ST-Elevation Myocardial Infarction. Prehospital Emergency Care 12:3, 395-403
CrossRef92
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef93
James M. Brophy. (2007) Risk stratification following non-ST segment elevation myocardial infarction: Is the glass half-full or half-empty?. Canadian Journal of Cardiology 23:13, 1080-1081
CrossRef94
Scott J. Denardo, Keith E. Davis, James E. Tcheng. (2007) Effectiveness and Safety of Reduced-Dose Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndrome Followed by Antiplatelet Therapy Alone for Percutaneous Coronary Intervention. The American Journal of Cardiology 100:9, 1376-1382
CrossRef95
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef96
Giuseppe Tarantini, Renato Razzolini, Angelo Ramondo, Massimo Napodano, Anna Manica, Enrico Favaretto, Sabino Iliceto. (2007) Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome. Journal of Cardiovascular Medicine 8:10, 799-802
CrossRef97
D. Härtel, E. Christel, J. Brockmeier, A. Cuneo, C. Zellerhoff, J. Götz, T. Hundhausen, T. Dammann, U. Tebbe. (2007) Verbesserung der Behandlung von Patienten mit akutem Koronarsyndrom durch Aufbau einer Netzwerkstruktur im ländlichen Raum. Notfall + Rettungsmedizin 10:6, 423-431
CrossRef98
Rohit Bhatheja, Debabrata Mukherjee. (2007) Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics 23:4, 709-735
CrossRef99
Fons Windhausen, Alexander Hirsch, Jan G.P. Tijssen, Jan Hein Cornel, Freek W.A. Verheugt, Margriet I. Klees, Robbert J. de Winter. (2007) ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non–ST-elevation acute coronary syndromes. Journal of Electrocardiology 40:5, 408-415
CrossRef100
Julio Núñez, Juan Sanchis, Eduardo Núñez, Vicent Bodi, Vicente Bertomeu-González, Maria J. Bosch, Enrique Santas, Lorenzo Fácila, Francisco J. Chorro, Cristina Gómez, Luciano Consuegra, Angel Llàcer. (2007) Prognostic differences between routine invasive and conservative strategies for the management of high-risk, non-ST segment acute coronary syndromes: Experience from two consecutive periods in a single center. European Journal of Internal Medicine 18:5, 409-416
CrossRef101
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef102
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef103
Stephen E. Van Horn, Calin V. Maniu. (2007) Management of non–ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America 91:4, 683-700
CrossRef104
E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
CrossRef105
Amy K. Saenger, Allan S. Jaffe. (2007) The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. Medical Clinics of North America 91:4, 657-681
CrossRef106
Eugenia Nikolsky, Gregg W Stone. (2007) Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiology 3:4, 345-364
CrossRef107
J. Dawn Abbott, Hanna N. Ahmed, Helen A. Vlachos, Faith Selzer, David O. Williams. (2007) Comparison of Outcome in Patients With ST-Elevation Versus Non–ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). The American Journal of Cardiology 100:2, 190-195
CrossRef108
G. Etienne Cramer, Peter C. Kievit, Marc A. Brouwer, Marinus H. de Keijzer, Hans E. Luijten, Freek W.A. Verheugt. (2007) Lack of concordance between a rapid bedside and conventional laboratory method of cardiac troponin testing: Impact on risk stratification of patients suspected of acute coronary syndrome. Clinica Chimica Acta 381:2, 164-166
CrossRef109
Enrique P. Gurfinkel, Ricardo Perez de la Hoz, Viviana M. Brito, Ernesto Duronto, Omar H. Dabbous, Joel M. Gore, Frederick A. Anderson. (2007) Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. International Journal of Cardiology 119:1, 65-72
CrossRef110
Barry A. Franklin. (2007) Lessons Learned From the COURAGE Trial: Generalizability, Limitations, and Implications. Preventive Cardiology 10:3, 117-120
CrossRef111
John J. Mahmarian, Craig M. Pratt. (2007) Reply. Journal of the American College of Cardiology 49:22, 2227-2228
CrossRef112
Philippe Gabriel Steg. (2007) Do the benefits of early invasive therapy for non-STE acute coronary syndromes persist with long-term follow-up?. Nature Clinical Practice Cardiovascular Medicine 4:5, 246-247
CrossRef113
Boden, William E., O'Rourke, Robert A., Teo, Koon K., Hartigan, Pamela M., Maron, David J., Kostuk, William J., Knudtson, Merril, Dada, Marcin, Casperson, Paul, Harris, Crystal L., Chaitman, Bernard R., Shaw, Leslee, Gosselin, Gilbert, Nawaz, Shah, Title, Lawrence M., Gau, Gerald, Blaustein, Alvin S., Booth, David C., Bates, Eric R., Spertus, John A., Berman, Daniel S., Mancini, G.B. John, Weintraub, William S., . (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine 356:15, 1503-1516
Full Text114
Fons Windhausen, Alexander Hirsch, Gerard T. Sanders, Jan P. Hein Cornel, Johan Fischer, Jan van Straalen, Jan G.P. Tijssen, Freek W.A. Verheugt, Robbert J. de Winter. (2007) N-terminal pro–brain natriuretic peptide for additional risk stratification in patients with non–ST-elevation acute coronary syndrome and an elevated troponin T: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. American Heart Journal 153:4, 485-492
CrossRef115
Gustavo B.F. Oliveira, Alvaro Avezum, Frederick A. Anderson, Andrzej Budaj, Omar H. Dabbous, Shaun G. Goodman, Philippe Gabriel Steg, Robert J. Goldberg, David Brieger, Keith A.A. Fox, Joel M. Gore, Christopher B. Granger. (2007) Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification. American Heart Journal 153:4, 493-499
CrossRef116
M. Weber, C. Hamm. (2007) Myokardinfarkt und instabile Angina Pectoris. Der Internist 48:4, 399-412
CrossRef117
Caroline Schmidt-Lucke, Heinz-Peter Schultheiss. (2007) Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. Vascular Health and Risk Management 3:2, 221-228
CrossRef118
Alexander Hirsch, Fons Windhausen, Jan GP Tijssen, Freek WA Verheugt, Jan Hein Cornel, Robbert J de Winter. (2007) Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. The Lancet 369:9564, 827-835
CrossRef119
Freek WA Verheugt. (2007) Are there differences in outcome following PCI between patients with STEMI and those with non-STEMI?. Nature Clinical Practice Cardiovascular Medicine 4:1, 18-19
CrossRef120
E.C. Bruno. (2007) Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. Yearbook of Emergency Medicine 2007, 102-103
CrossRef121
Rosa Ana Hernández Antolín, Felipe Fernández-Vázquez, José Moreu Burgos, Ramón López Palop. (2007) Cardiología intervencionista 2006. Revista Española de Cardiología 60, 19-32
CrossRef122
Eng Wei Tang, Cheuk-Kit Wong, Peter Herbison. (2007) Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. American Heart Journal 153:1, 29-35
CrossRef123
Xavier García-Moll, Alfredo Bardají, Joaquín Alonso, Héctor Bueno. (2007) Actualización en cardiopatía isquémica 2006. Revista Española de Cardiología 60, 3-18
CrossRef124
Hae-Chang Jeong, Myung Ho Jeong, Young Keun Ahn, Sung Chull Chae, Young Jo Kim, Seung Ho Hur, Dong Hoon Choi, Jung Han Yoon, Jei Keon Chae, Doo Il Kim, Bon Kwon Koo, Jin Yong Hwang, Seok Kyu Oh, Kee Sik Kim, Kyung Tae Jeong, Chong Jin Kim, Wook Sung Chung, Yang Soo Jang, . (2007) In-Hospital Outcome According to the Initial Management and the "Thrombolysis in Myocardial Infarction Risk Score" of Acute Non-ST Segment Elevation Myocardial Infarction. Korean Circulation Journal 37:11, 550
CrossRef125
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef126
Stella M. Macín, Eduardo R. Perna, María L. Coronel, Jorge O. Kriskovich, Pablo A. Bayol, Valeria A. Franciosi, Jorge L. Riera-Stival, Bilda González-Arjol, Jorge R. Badaracco. (2006) Influencia de la concentración de glucemia en el momento del ingreso en la evolución a largo plazo de los pacientes con síndrome coronario agudo. Revista Española de Cardiología 59:12, 1268-1275
CrossRef127
John J. Mahmarian, Leslee J. Shaw, Neil G. Filipchuk, Habib A. Dakik, Sherif S. Iskander, Terrence D. Ruddy, Milena J. Henzlova, Felix Keng, Adel Allam, Lemuel A. Moyé, Craig M. Pratt. (2006) A Multinational Study to Establish the Value of Early Adenosine Technetium-99m Sestamibi Myocardial Perfusion Imaging in Identifying a Low-Risk Group for Early Hospital Discharge After Acute Myocardial Infarction. Journal of the American College of Cardiology 48:12, 2448-2457
CrossRef128
John J. Mahmarian, Habib A. Dakik, Neil G. Filipchuk, Leslee J. Shaw, Sherif S. Iskander, Terrence D. Ruddy, Felix Keng, Milena J. Henzlova, Adel Allam, Lemuel A. Moyé, Craig M. Pratt. (2006) An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. Journal of the American College of Cardiology 48:12, 2458-2467
CrossRef129
Anthony A. Bavry, Dharam J. Kumbhani, Andrew N. Rassi, Deepak L. Bhatt, Arman T. Askari. (2006) Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:7, 1319-1325
CrossRef130
Abelardo Martinez-Rumayor, James L. Januzzi. (2006) Non-ST Segment Elevation Acute Coronary Syndromes: A Comprehensive Review. Southern Medical Journal 99:10, 1103-1110
CrossRef131
Barry A. Franklin. (2006) Coronary revascularization and medical management of coronary artery disease: changing paradigms and perceptions. European Journal of Cardiovascular Prevention & Rehabilitation 13:5, 669-673
CrossRef132
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef133
Richard G Bach. (2006) The early invasive strategy revisited: FRISC II at 5 years. The Lancet 368:9540, 966-969
CrossRef134
William H. Wehrmacher. (2006) Unstable angina treatment 2006 Update. Comprehensive Therapy 32:3, 144-146
CrossRef135
Robbert J. de Winter. (2006) Commentary on Clinical Guidelines and Practice. Journal of the American College of Cardiology 48:6, 1136-1138
CrossRef136
Bo Lagerqvist, Steen Husted, Fredrik Kontny, Elisabeth Ståhle, Eva Swahn, Lars Wallentin. (2006) 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. The Lancet 368:9540, 998-1004
CrossRef137
Cynthia M. Westerhout, Yuling Fu, Michael S. Lauer, Stefan James, Paul W. Armstrong, Eyad Al-Hattab, Robert M. Califf, Maarten L. Simoons, Lars Wallentin, Eric Boersma. (2006) Short- and Long-Term Risk Stratification in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:5, 939-947
CrossRef138
Dean J. Kereiakes, Elliott M. Antman. (2006) Clinical Guidelines and Practice. Journal of the American College of Cardiology 48:6, 1129-1135
CrossRef139
Michel R Hoenig, Jenny Doust, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2006. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. .
CrossRef140
Robert P. Giugliano, Eugene Braunwald. (2006) The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 48:2, 386-395
CrossRef141
W. Grimm, B. Maisch. (2006) Behandlungspfad „Akutes Koronarsyndrom“. Der Internist 47:7, 699-706
CrossRef142
David H. Fitchett, Bjug Borgundvaag, Warren Cantor, Eric Cohen, Sanjay Dhingra, Stephen Fremes, Milan Gupta, Michael Heffernan, Heather Kertland, Mansoor Husain, Anatoly Langer, Eric Letovsky, Shaun G. Goodman. (2006) Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. Canadian Journal of Cardiology 22:8, 663-677
CrossRef143
P. Nair, A. Roguin. (2006) Statins and the acute coronary syndrome: ‘the early bird catches the worm’. International Journal of Clinical Practice 60:6, 716-727
CrossRef144
José A. Álvarez-Tamargo, Eugenio Simarro Martín-Ambrosio, Enrique Romero-Tarín, Vicente J. Albadalejo-Salinas, Jesús M. de la Hera, María Martín-Fernández, Marcos G. Aguado, Vicente Barriales-Álvarez, Cesar Morís de la Tassa. (2006) Comparación angiográfica de los criterios e índices de alto riesgo para ergometría convencional en pacientes diagnosticados de angina inestable en función del sexo, la edad o el uso de fármacos bradicardizantes. Revista Española de Cardiología 59:5, 448-457
CrossRef145
. (2006) Wat is de rol van vroege invasieve strategie bij acuut coronair syndroom zonder ST-elevatie?. MFM 44:4, 103-104
CrossRef146
Simon R. Dixon, Cindy L. Grines, William W. O’Neill. (2006) The Year in Interventional Cardiology. Journal of the American College of Cardiology 47:8, 1689-1706
CrossRef147
Spencer B King. (2006) Do elderly patients with non-ST-segment elevation acute coronary syndromes benefit from early invasive treatment?. Nature Clinical Practice Cardiovascular Medicine 3:4, 188-189
CrossRef148
Michel E Bertrand. (2006) Is early invasive treatment superior to selectively invasive treatment in patients with acute coronary syndromes?. Nature Clinical Practice Cardiovascular Medicine 3:3, 130-131
CrossRef149
Mark A. Kudes, Ronald G. Schwartz. (2006) Noninvasive monitoring of medical therapy. Current Cardiology Reports 8:2, 139-146
CrossRef150
Ronald G. Schwartz, Mark A. Kudes. (2006) Monitoring effectiveness of medical therapy in 2006. Journal of Nuclear Cardiology 13:2, 184-190
CrossRef151
Arno Breeman, Jan Paul Ottervanger, Eric Boersma, Giuseppe De Luca. (2006) Coronary revascularization for non-ST elevation acute coronary syndrome: state of the art. Journal of Cardiovascular Medicine 7:2, 108-113
CrossRef152
William E Boden. (2006) What is the optimum role and timing of early invasive management of patients with acute coronary syndromes?. Nature Clinical Practice Cardiovascular Medicine 3:2, 72-73
CrossRef153
B.J. Gersh. (2006) Early Invasive Versus Selectively Invasive Management for Acute Coronary Syndromes. Yearbook of Cardiology 2006, 234-236
CrossRef154
M. Dellborg. (2006) PCI in ST-elevation infarction – One flew over the cuckoo's nest. Scandinavian Cardiovascular Journal 40:1, 8-10
CrossRef155
Rosa A. Hernández Antolín, Felipe Fernández Vázquez, José Moreu Burgos, Ramón López Palop. (2006) Cardiología intervencionista 2005. Revista Española de Cardiología 59, 38-49
CrossRef156
Robert K. Riezebos, Eelko Ronner, Jan G. P. Tijssen, Gert‐Jan Laarman. (2006) NT‐ProBNP serum levels reflect severity and extent of ischemia in patients admitted with non‐ST‐elevation acute coronary syndrome. Acute Cardiac Care 8:1, 51-57
CrossRef157
W FRISHMAN. (2006) Early Invasive Versus Selectively Invasive Management for Acute Coronary Syndromesde Winter RJ, for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators (Academisch Medisch Centrum, Amsterdam; et al) N Engl J Med 353:1095–1104, 2005§. Yearbook of Medicine 2006, 320-322
CrossRef158
(2005) Management of Acute Coronary Syndromes. New England Journal of Medicine 353:25, 2714-2718
Full Text159
Francesc X. Borrás Pérez. (2005) Los análisis de coste-efectividad como guía para la implementación clínica de los nuevos tratamientos. Revista Española de Cardiología 58:12, 1377-1380
CrossRef160
Boden, William E., . (2005) Acute Coronary Syndromes without ST-Segment Elevation — What Is the Role of Early Intervention?. New England Journal of Medicine 353:11, 1159-1161
Full Text
- Letters
